Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 252

The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.

Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine

Open access
Satija, Neeraj Kumar, Singh, Vimal Kishor, Verma, Yogesh Kumar, Gupta, Pallavi, Sharma, Shilpa, Afrin, Farhat, Sharma, Menka, Sharma, Pratibha, Tripathi, R. P., Gurudutta, G. U.·2009·Journal of Cellular and Molecular Medicine

Abstract

Introduction Mesenchymal stem cells and its characteristics Experimental/preclinical MSC‐based studies Clinical studies Challenges and future prospects Mesenchymal stem cells (MSCs), adherent fibroblastoid cells, present in bone marrow and many other tissues can be easily isolated and expanded in vitro. They are capable of differentiating into different cell types such as osteoblasts, chondrocytes, adipocytes, cardiomyocytes, hepatocytes, endothelial cells and neuronal cells. Such immense plasticity coupled with their ability to modulate the activity of immune cells makes them attractive for stem cell‐based therapy aimed at treating previously incurable disorders. Preclinical studies have reported successful use of MSCs for delivering therapeutic proteins and repairing defects in a variety of disease models. These studies highlighted the in vivo potential of MSCs and their ability to home to injury sites and modify the microenvironment by secreting paracrine factors to augment tissue repair. Their therapeutic applicability has been widened by genetic modification to enhance differentiation and tissue targeting, and use in tissue engineering. Clinical trials for diseases such as osteogenesis imperfecta, graft‐versus‐host disease and myocardial infarction have shown some promise, demonstrating the safe use of both allogeneic and autologous cells. However, lack of knowledge of MSC behaviour and responses in vitro and i n vivo force the need for basic and animal studies before heading to the clinic. Contrasting reports on immunomodulatory functions and tumorigenicity along with issues such as mode of cell delivery, lack of specific marker, low survival and engraftment require urgent attention to harness the potential of MSC‐based therapy in the near future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1582-4934.2009.00857.x

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 183 references

Cited by

See all 252

Metadata

Authors
Satija, N. K., Singh, V. K., Verma, Y. K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R. P., & Gurudutta, G. U.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2009-11
Volume
13
Issue
11-12
Pages
4385-4402
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W1964674805
Cited by
252
References
183
FWCI
10.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine. https://app.cochat.ai/papers/10.1111/j.1582-4934.2009.00857.x
The paper
Satija, N. K., Singh, V. K., Verma, Y. K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R. P., & Gurudutta, G. U. (2009). Mesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2009.00857.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.